Ai meets genomics: predictive oncology breakthrough coincides with regeneron's $256m 23andme acquisition

Company leverages more than twenty years of drug response data derived from massive biobank of live cell tumor samples company leverages more than twenty years of drug response data derived from massive biobank of live cell tumor samples
POAI Ratings Summary
POAI Quant Ranking